Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause Exposure during pregnancy? 2,342 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 2,342 reports of Exposure during pregnancy have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 2.4% of all adverse event reports for TOCILIZUMAB.

2,342
Reports of Exposure during pregnancy with TOCILIZUMAB
2.4%
of all TOCILIZUMAB reports
843
Deaths
888
Hospitalizations

How Dangerous Is Exposure during pregnancy From TOCILIZUMAB?

Of the 2,342 reports, 843 (36.0%) resulted in death, 888 (37.9%) required hospitalization, and 935 (39.9%) were considered life-threatening.

Is Exposure during pregnancy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 2,342 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause Exposure during pregnancy?

ADALIMUMAB (4,556) ACETAMINOPHEN (4,395) INFLIXIMAB (3,636) PREDNISONE (2,906) HYDROXYCHLOROQUINE (2,610) RITUXIMAB (2,468) CETIRIZINE (2,435) FOLIC ACID (2,318) LEFLUNOMIDE (2,264) METHOTREXATE (2,222)

Which TOCILIZUMAB Alternatives Have Lower Exposure during pregnancy Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All Exposure during pregnancy Reports All Drugs Causing Exposure during pregnancy TOCILIZUMAB Demographics